FMFelix Mogaka

Felix Mogaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Felix Mogaka has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel Multiplex Near–Point-of-Care PCR Assay for Detecting Sexually Transmitted Infections Among PrEP Users in Western Kenya: Protocol for a Cross-Sectional Pilot Study With an Epidemiological Assessment

    by Aarman Sohaili, Felix Mogaka, Zoïe Alexiou, Victor Ocholla Omollo, Servaas A Morre, Elizabeth Anne Bukusi, Pierre P M Thomas

    Background: The global impact of sexually transmitted infections (STIs) significantly affects low- and middle-income countries (LMIC). Iin Kenya, where access to STI diagnostics is limited, effective diagnostic solutions are critically needed. Nucleic acid amplification tests are considered the laboratory gold standard for detecting pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae due to their high sensitivity and specificity. However, these methods typically require centralized laboratories, trained personnel, and longer turnaround times. FlashDx is a near–point-of-care molecular diagnostic platform designed to address these challenges by integrating automated sample processing and multiplex pathogen detection within a compact system suitable for decentralized use. Objective: The primary aim of this study is to validate the performance of the FlashDx STI multiplex assay for detecting STIs including Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , Mycoplasma genitalium , Mycoplasma hominis , and Ureaplasma species compared with the reference Conformité Européenne In-Vitro Diagnostic (CE-IVD)-D dual real-time polymerase chain reaction (rtPCR) from Mikrogen. Methods: We propose a comparative cross-sectional study conducted with up to 400 young pre-exposure prophylaxis (PrEP) users aged between 15 years and 55 years at the Kenya Medical Research Institute Center for Microbiology Research Care and Training Program research site in Kisumu, Kenya. Urine samples were collected and analyzed using the FlashDx STI multiplex chip-based assay to detect 6 STIs, with results confirmed by the CE-IVD-D certified Mikrogen assay in the Netherlands. Participants were recruited in Kisumu, Kenya, from existing HIV prevention programs and sexual health services. Diagnostic performance will be assessed by calculating sensitivity, specificity, positive predictive value, and negative predictive value with 95% CIs. Descriptive and epidemiological analyses will summarize participant characteristics, behavioral risk factors, and the prevalence of STI infections within the cohort. Epidemiological data generated will include prevalence rates for all 6 STIs, providing an overview of STI prevalence with external validation to ensure accuracy and reliability. Results: The study was funded by Microbe & Lab, with in-kind contributions from the Kenya Medical Research Institute (KEMRI) Centre for Microbiology Research (CMR) Research Care and Training Program (RCTP). Data collection was conducted between April 2025 and June 2025 at the KEMRI research site in Kisumu, Kenya. A total of 400 participants were recruited for the study. The study is currently in the data analysis phase. Statistical evaluation of the diagnostic performance of the FlashDx STI multiplex assay is being carried out. In parallel, epidemiological analyses are being conducted. Final results and associated epidemiological findings are expected to be completed and prepared for publication in the summer of 2026. Conclusions: The findings from this study are expected to show the FlashDx STI multiplex assay as an effective point-of-care system for diagnosing 6 common STIs in settings such as Kenya. By demonstrating its usability, accuracy, and reliability, the FlashDx assay could be considered for broader implementation in clinical settings across Kenya and other LMIC.

  • Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis

    by Fredericka Albertina Sesay, Kevin Oware, Lauren R Violette, Deborah Donnell, Josephine B Odoyo, Victor Omollo, Felix O Mogaka, R Scott McClelland, Jennifer E Balkus, Elizabeth A Bukusi, et al.

    Doxycycline treats and prevents several bacterial and parasitic infections and has been proposed as a possible treatment for Trichomonas vaginalis. Nested in a trial of doxycycline postexposure prophylaxis among cisgender women in Kenya, we conducted a secondary analysis of incident T. vaginalis infections. Among 224 cisgender women randomized to doxycycline postexposure prophylaxis and 225 to standard-of-care, there were 27 T. vaginalis diagnoses in the doxycycline postexposure prophylaxis group and 29 in the standard-of-care group (RR: 0.96, 95% CI: 0.54–1.73, P = .9). Understanding doxycycline postexposure prophylaxis's impact on T. vaginalis remains an important public health question that warrants further investigation.

  • Open Access

    Stakeholder perspectives on integrating doxycycline postexposure prophylaxis into Kenyan HIV PrEP programmes

    by Felix Ong’ERa Mogaka, Benn Kwach, Alfred Odira, Gabrielle O’MAlley, Mary Hearst, Elizabeth A Bukusi, Jenell Stewart

    Objectives Doxycycline postexposure prophylaxis (doxyPEP) is an efficacious sexually transmitted infection (STI) prevention strategy. Implementation guidelines recommend a focus on people with prior STIs and/or those taking HIV pre-exposure prophylaxis (PrEP), but trial results are insufficient for interventions to enter guidelines and clinical practice. The purpose of this paper is to describe potential barriers and facilitators for successful implementation strategies of doxyPEP in resource-limited settings. Methods This qualitative study explored the perceived acceptability, feasibility and sustainability of integrating doxyPEP for STI prevention into Kenyan HIV PrEP programmes. Semistructured interviews were conducted with policymakers, healthcare providers and HIV PrEP users. The interviews were recorded, transcribed and translated to English. Analysis was completed using Dedoose software using deductive reasoning based on the Consolidated Framework for Implementation Research. Results Forty interviews (7 policymakers, 16 HIV PrEP users, 17 healthcare providers) were conducted between August 2022 and April 2023. Collectively, study participants found doxyPEP to be an acceptable strategy and understood its potential use among HIV PrEP users. However, participants noted several considerations such as the relative advantage, quality and evidence strength, and tension for change alongside the needs, resources and knowledge of the recipient. Integrating doxyPEP into HIV PrEP programmes was deemed feasible, but there were concerns over long-term sustainability, antimicrobial resistance (AMR), surveillance, cost, pill burden and compatibility, and high workload for HIV PrEP providers. Establishing sustainable practice needs to consider costs, external policies, incentives to participate and engaging providers and recipients in the process. Conclusion Kenyan HIV/STI policymakers, healthcare providers and HIV PrEP users perceived doxyPEP for STI prevention to be acceptable and feasible when addressing local contextual factors. Potential for sustainability was recognised if programmes can address concerns, including AMR, pill burden and additional workload for health professionals, prior to the implementation of doxyPEP into HIV PrEP programmes.


  • Open Access

    Implementing long-acting injectable HIV pre-exposure prophylaxis services at private pharmacies in Kenya: Client, pharmacy provider, and key stakeholder perspectives on potential challenges and opportunities

    by Stephanie Roche, Kevin Kamolloh, Nicholas Thuo, Maurice Opiyo, Vallery Ogello, Alfred Odira, Emmah Owidi, Perez Ochwal, Marion Hewa, Lydia Adiema, et al.

    Introduction Maximizing the impact of new and forthcoming long-acting injectable HIV pre-exposure prophylaxis (PrEP) products will require novel delivery approaches that widen accessibility and prioritize clients’ needs and preferences. To understand the potential barriers and facilitators to delivering injectable PrEP via private pharmacies in Kenya, we conducted qualitative formative research. Methods From July to September 2023, we interviewed pharmacy providers, pharmacy clients, and other key stakeholders of HIV service delivery in Central and Western Kenya. Our purposive sample included some providers and clients with prior experience delivering or obtaining oral PrEP at a pharmacy as part of a pilot study and some without such experience. We analyzed verbatim transcripts thematically using a combination of inductive and deductive approaches, the latter informed by the Consolidated Framework for Implementation Research (CFIR). Results We interviewed 25 pharmacy clients, 16 pharmacy providers, and 9 key stakeholders. Each group was ∼50% female, and median age among clients was 25 (IQR 23-29). Overall, participants supported the idea of pharmacy-based injectable PrEP delivery. Anticipated facilitators included perceived benefits of injectable over oral PrEP; characteristics of pharmacies (e.g., long operating hours) that could fulfill clients’ need for accessible, fast, and private injectable PrEP services; and existing skillsets of pharmacy providers, especially those already trained on injectable contraception. Anticipated barriers included gaps in enabling policy; pharmacies’ lack of integration with the public health sector, such as its health information system; low client knowledge of and/or ability to pay for injectable PrEP; and pharmacy staffing and compensation structures that could disincentivize providers. Conclusions Participants in this study expressed cautious optimism that private pharmacies could be an effective delivery channel for injectable PrEP in Kenya. If private pharmacies facilitate access to and use of injectable PrEP, they could play a pivotal role in ending HIV as a public health threat.

  • Challenges and Solutions to STI Control in the Era of HIV and STI Prophylaxis

    by Felix Ong’eRa Mogaka, Jenell Stewart, Victor Omollo, Elizabeth Bukusi

    Purpose of Review This article reviews current efforts to control bacterial sexually transmitted infections (STIs) among HIV pre-exposure prophylaxis (PrEP) users and outlines the opportunities and challenges to controlling STIs within HIV PrEP programs. Recent Findings The incidence of STIs continues to rise globally especially among HIV PrEP users, with an estimated 1 in 4 PrEP users having a curable bacterial STI. STIs and HIV comprise a syndemic needing dual interventions. The majority of STIs are asymptomatic, and when testing is available, many STIs occur in extragenital sites that are missed when relying on urine testing or genital swabs. Optimal testing and treatment, including testing for antimicrobial resistance, pose difficulties in high income countries and is essentially non-existent in most low- and middle-income countries. Novel STI primary prevention strategies, like doxycycline post-exposure prophylaxis (PEP) for STI prevention, have proven to be highly efficacious in some populations. A few jurisdictions have issued normative guidelines and position statements for doxycycline PEP; however, clinical standards for implementation and data on public health impact are limited. Summary STI incidence rates are high and rising in sexually active populations. Sexual health programs should leverage the expansion of HIV PrEP delivery services to integrate STI testing, surveillance, and novel STI prevention services.


  • Qualitative Analysis Using Social Maps to Explore Young Women's Experiences With Social Support of their Oral PrEP Use in Kenya and South Africa

    by Ariana W. K. Katz, Sarah Roberts, Elzette Rousseau, Makhosazane Nomhle Khoza, Felix Mogaka, Elizabeth Bukusi, Sinead Delany-Moretlwe, Linda-Gail Bekker, Jennifer F. Morton, Rachel Johnson, et al.

    Daily oral pre-exposure prophylaxis (PrEP) adherence is challenging. We explored African adolescent girls and young women's (AGYW) perceptions of the social influencers of their PrEP use and the social influencers' PrEP knowledge and support (six focus group discussions; 33 South African and Kenyan AGYW) in the Prevention Options for Women Evaluation Research demonstration project. Participants completed a social mapping exercise indicating strength and direction of influence of members in their social networks. Mothers and counselors were identified as positive influencers and most influential by >50% of participants, sex partners were labeled negative influencers or both positive and negative, and best friends were mostly positive influencers. HIV- and PrEP-related stigma were the major reasons influencers were identified as negative. Participants wanted their social networks to be better educated about PrEP by someone other than the AGYW themselves (e.g., clinic staff) and to support their PrEP use. To improve PrEP adherence, community- and peer-based PrEP sensitization and delivery interventions should be evaluated.


  • Open Access

    Cost of pre-exposure prophylaxis delivery in family planning clinics to prevent HIV acquisition among adolescent girls and young women in Kisumu, Kenya

    by Valentine Wanga, Kathryn Peebles, Alfred Obiero, Felix Mogaka, Victor Omollo, Josephine B. Odoyo, Jennifer F. Morton, Elizabeth A. Bukusi, Connie Celum, Jared M. Baeten, et al.

    Introduction: Oral pre-exposure prophylaxis (PrEP) is increasingly being implemented in sub-Saharan Africa. Adolescent girls and young women (AGYW) in Kenya contribute more than half of all new infections among young people aged 15–24 years, highlighting the need for evidence on the cost of PrEP in real-world implementation to inform the budget impact, cost-effectiveness, and financial sustainability of PrEP programs.Methods: We estimated the cost of delivering PrEP to AGYW enrolled in a PrEP implementation study in two family planning clinics in Kisumu county, located in western Kenya. We derived total annual costs and the average cost per client-month of PrEP by input type (variable or fixed) and visit type (initiation or follow-up). We estimated all costs as implemented in the study, and under implementation by the Kenyan Ministry of Health (MoH), both at the program volume observed and if the facilities were delivering PrEP at full capacity (scaled-MoH).Results: For the costing period between March 2018 and March 2019, 615 HIV-negative women contributed 1,128 (502 initiation and 626 follow-up) visits. The average cost per client-month of PrEP dispensed per study protocol and per the MoH scenario was $28.92 and $14.52, respectively. If the MoH scaled the program so that facilities could see PrEP clients at capacity, the average cost per client-month of PrEP was $10.88. Medication costs accounted for the largest proportion of the total annual costs (48% in MoH scenario and 65% in the scaled-MoH scenario).Conclusions: Using data from a PrEP implementation program, we found that the cost per client-month of PrEP dispensed is reduced by 62% if PrEP delivery at the two clinics is scaled up by the MoH. Our findings are valuable for informing local resource allocation and budgetary cost projections for scale-up of PrEP delivery to AGYW. Additionally, previous cost-effectiveness studies have been limited by the use of fixed assumptions of the cost of PrEP per person-month. Our study provides cost estimates from practical data which will better inform cost-effectiveness and budget impact analyses.